Kidney drug study halted early, but safety data collected

NCT ID NCT05656040

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 26 times

Summary

This early-stage study tested a single dose of an experimental drug called MK-2060 in 14 people with advanced chronic kidney disease. The main goal was to check for side effects, especially bleeding, and to measure how the drug moves through the body. Only the first part of the study was completed; the later parts were not started for reasons unrelated to safety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Advanced Pharma CR, LLC ( Site 0006)

    Miami, Florida, 33147, United States

  • Alliance for Multispecialty Research, LLC ( Site 0002)

    Knoxville, Tennessee, 37920, United States

  • Genesis Clinical Research, LLC ( Site 0004)

    Tampa, Florida, 33603, United States

  • Velocity Clinical Research, New Smyrna Beach ( Site 0003)

    Edgewater, Florida, 32132, United States

Conditions

Explore the condition pages connected to this study.